Drug class

Antiandrogens clinical trials

A class of medicines: the studies that test any of its 10 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Androgen Antagonists.

studies test it: 479
open now: 92
in phase 3: 99
first study started: 1994

Get an email when these change. Save the antiandrogens studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Medicines in this class

Studies that test each. A study of two counts under both, and once above.

Enzalutamide: 176
Bicalutamide: 94
Apalutamide: 85
Darolutamide: 77
Flutamide: 32
Cyproterone: 16
Nilutamide: 4
Cyproterone acetate, ethinyl estradiol drug combination: 4
Hydroxyflutamide: 3
Chlormadinone: 2

Studies by the year they started

475 studies that test it; most in 2017 (38); 2 more planned to start later

Studies that test Antiandrogens, by start year
Year	Studies
1994	2
1995	5
1996	3
1997	1
1998	2
1999	3
2000	7
2001	6
2002	3
2003	7
2004	6
2005	8
2006	6
2007	3
2008	4
2009	8
2010	11
2011	15
2012	13
2013	23
2014	35
2015	33
2016	32
2017	38
2018	18
2019	25
2020	32
2021	27
2022	16
2023	22
2024	28
2025	12
2026	21

By phase

A phase 1/2 study counts in both.

Early Phase 1: 7
Phase 1: 112
Phase 2: 252
Phase 3: 99
Phase 4: 29
No phase: 16

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Prostatic Neoplasms: 261
Breast Neoplasms: 18
Polycystic Ovary Syndrome: 11
Prostatic Neoplasms, Castration-Resistant: 10
Neoplasms: 9
Triple Negative Breast Neoplasms: 8
Salivary Gland Neoplasms: 6
Ovarian Neoplasms: 4
Depressive Disorder, Major: 4
Neoplasm Metastasis: 2
Urinary Bladder Neoplasms: 2
Carcinoma, Renal Cell: 2

Who runs them

Industry 157 · Other 322

Pfizer (16) · Bayer (16) · Aragon Pharmaceuticals, Inc. (15) · AstraZeneca (15) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (13) · M.D. Anderson Cancer Center (13) · Memorial Sloan Kettering Cancer Center (11) · Astellas Pharma Global Development, Inc. (11)

Studies

Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing one of them · 479

See all 479 studies that test one of the antiandrogens →